Clopidogrel withdrawal: Is there a “rebound” phenomenon?

Summary

Dual antiplatelet therapy with aspirin and clopidogrel is routinely indicated in patients with acute coronary syndromes and following percutaneous coronary intervention to reduce the risk of cardiovascular mortality and ischaemic events. Although clinical guidelines recommend aspirin lifelong and clopidogrel for between one and 12 months, depending upon the indication, the optimal duration of clopidogrel therapy actually remains contentious. Premature cessation of clopidogrel in patients receiving drug-eluting stents is a clear risk factor for stent thrombosis, but recent clinical studies have also demonstrated a link between “appropriate” cessation of clopidogrel and clustering of adverse clinical events. It has been suggested that this may be due to a “rebound” prothrombotic and/ or proinflammatory response associated with clopidogrel withdrawal. This review will examine the defini- tion and concept of a “rebound” phenomenon associated with clopidogrel cessation as well as the likely mechanisms behind this effect. Within the context of clinical event clustering after clopidogrel cessation, we will also discuss (i) the clinical importance of clopidogrel and the increasing uncertainty surrounding optimal duration of therapy, (ii) the antiplatelet and anti-inflammatory properties of clopidogrel and, in particular, its influence on arachidonic acid pathways traditionally thought to be mediated predominantly by aspirin and (iii) the role of newer, more potent antiplatelet agents and potential changes to anti-platelet therapy prescribing guidelines in the future.

Keywords

Clopidogrel cessation - rebound - platelet aggregation - stent thrombosis - inflammation

• References

• 1 Yusuf S, Zhao F, Mehta SR. et al. for the Clopidogrel in Unstable Angina to Prevent Recurrent Ischaemic Events (CURE) Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
• 2 Sabatine MS, Cannon CP, Gibson CM. et al. for the Clopidogrel as Adjunctive Reperfusion Therapy– Thrombolysis In Myocardial Infarction 28 (CLARITY-TIMI 28) Trial Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-189.
• 3 Chen ZM, Jiang LX, Chen YP. et al. for the Clopidogrel and Metoprolol in Myocardial Infarction (COMMIT) Trial Investigators. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621.
• 4 Steinhubl S, Berger P, Mann J. et al. for the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. J Am Med Assoc 2002; 288: 2411-2420.
• 5 Mehta S, Yusuf S, Peters R. et al. for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pre-treatment with clopidogrel and aspirin followed by long term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
• 6 Iakovou I, Schmidt T, Bonizzoni E. et al. Incidence, predictors and outcomes of thrombosis after successful implantation of drug eluting stents. J Am Med Assoc 2005; 293: 2126-2130.
• 7 Moore RK, Lowe R, Grayson AD. et al. A study comparing the incidence and predictors of creatinine kinase MB and troponin T release after coronary angioplasty. Does clopidogrel preloading reduce myocardial necrosis following elective percutaneous coronary intervention? Int J Cardiol 2007; 116: 93-97.
• 8 Patti G, Colonna G, Pasceri V. et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Results from the ARMYDA-2 study. Circulation 2005; 111: 2099-2106.
• 9 Nienhuis MB, Ottervanger JP, Miedema K. et al. Pretreatment with clopidogrel and postprocedure troponin elevation after elective percutaneous coronary intervention. Thromb Haemost 2006; 95: 337-340.
• 10 Hermann A, Rauch BH, Braun M. et al. Platelet CD40 ligand (CD40L)- subcellular localisation, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82.
• 11 Antonino M, Mahla E, Bliden K. et al. Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. Am J Cardiol 2009; 103: 1546-1550.
• 12 Quinn M, Bhatt D, Zidar F. et al. Effect of clopidogrel pre-treatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004; 93: 679-684.
• 13 Shankar H, Garcia A, Prabhakar J. et al. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. J Thromb Haemost 2006; 4: 638-647.
• 14 Armstrong PC, Dhanji AR, Tucker AT. et al. Reduction of platelet thromboxane A2 production ex-vivoand in-vivoby clopidogrel therapy. J Thromb Haemost 2010; 8: 613-615.
• 15 Hobson A, Qureshi Z, Banks P. et al. Effects of clopidogrel on “aspirin-specific” pathways of platelet inhibition. Platelets 2009; 20: 386-390.
• 16 Dropinsky J, Jakiela B, Sanak M. et al. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. Thromb Haemost 2007; 98: 201-209.
• 17 Cattaneo M, Gachet C, Cazenave JP. et al. Adenosine diphosphate (ADP) does not induce thromboxane A2 generation in human platelets. Blood 2002; 99: 3868-3870.
• 18 Berger PB. Optimal duration of clopidogrel use after implantation of drug-eluting stents-still in doubt. N Engl J Med 2010; 362: 1441-1443.
• 19 van Werkum J, Heestermans A, Zomer C. et al. The Dutch Stent Thrombosis Registry. Predictors of coronary stent thrombosis. J Am Coll Cardiol 2009; 53: 1399-1409.
• 20 Spertus J, Kettelkamp R, Vance C. et al. Prevalence, predictors and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement. Results from the PREMIER registry. Circulation 2006; 113: 2803-2809.
• 21 Airoldi F, Colombo A, Morici N. et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116: 745-754.
• 22 Ho M, Peterson E, Wang L. et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. J Am Med Assoc 2008; 299: 532-539.
• 23 Ho M, Tsai T, Wang T. et al. Adverse events after stopping clopidogrel in post-acute coronary syndrome patients. Insights from a large integrated healthcare delivery system. Circ Cardiovasc Qual Outcomes 2010; 3: 303-308.
• 24 Schömig A, Neumam FJ, Kastrati A. et al. A randomised comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089.
• 25 Bertrand ME, Legrand V, Boland J. et al. Randomized multicentre comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoagulation vs Aspirin and Ticlopidine (FANTASTIC) Study. Circulation 1998; 98: 1597-1603.
• 26 Leon M, Baim D, Popma J. et al for the Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting. N Engl J Med 1998; 339: 1665-1671.
• 27 Bertrand ME, Rupprecht HJ, Urban P. et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000; 102: 624-629.
• 28 Bhatt DL, Bertrand ME, Berger PB. et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39: 9-14.
• 29 Bassand JP, Hamm CW, Ardissino D. et al. Task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-1660.
• 30 Van de Werf F, Bax J, Betriu A. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
• 31 Grines C, Bonow R, Casey Jr D. et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115: 813-818.
• 32 Silber S, Albertsson P, Aviles F. et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-847.
• 33 Kachulakanti PK, Chu WW, Torguson R. et al. Correlates and long term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006; 113: 1108-1113.
• 34 Eisenstein EL, Anstrom KJ, Kong DF. et al. Clopidogrel use and long term clinical outcomes in after drug eluting stent implantation. J Am Med Assoc 2007; 297: 159-168.
• 35 Park DW, Park SW, Park KH. at al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long term follow up. Am J Cardiol 2006; 98: 352-356.
• 36 Dean J, Yujie Z, Yingxin Z. et al. Prolonged dual antiplatelet therapy improves clinical outcomes in high-risk patients implanted with sirolimus-eluting stents. Clin Cardiol 2009; 32: 164-168.
• 37 Banerjee S, Varghese C, Samuel J. et al. Comparison of the impact of short (<1 year) and long-term (> 1year) clopidogrel use following percutaneous coronary intervention on mortality. Am J Cardiol 2008; 102: 1159-1162.
• 38 Park SJ, Park DW, Kim YH. et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362: 1374-1382.
• 39 http://clinicaltrials.gov/ct2/show/NCT00977938?term=DAPT+and+antiplatelet+therapy&rank=3
• 40 Angiolillo D, Bernardo E, Palazuelos J. et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions – Results of a randomised study. Thromb Haemost 2008; 99: 161-168.
• 41 CURRENT-OASIS 7 Investigators. Mehta SR, Bassand JP, Chrolavicius S. et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl Med 2010; 363: 930-942.
• 42 Mehta SR, Tanguay JF, Eikelboom JW. on behalf of the CURRENT-OASIS 7 Trial Investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010 Epub ahead of print.
• 43 Wiviott SD, Braunwald E, McCabe CH. et al for the TRITON-TIMI 38 Investigators. Prasugrel vs clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
• 44 Wallentin L, Becker RC, Budaj A. et al for the PLATO investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
• 45 Montalescot G, Sideris G, Cohen R. et al. Prasugrel compared with high dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 2010; 103: 213-223.
• 46 Becker RC, Gurbel PA. Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. Thromb Haemost 2010; 103: 535-544.
• 47 Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Haemost 2005; 31: 174-183.
• 48 Savi P, Pereillo JM, Uzabiaga MF. et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896.
• 49 Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008; 99: 466-472.
• 50 Goto S, Tamura N, Eto K. et al. Functional significance of adenosine 5’-diphosphate receptor (P2Y12) in platelet activation initiated by binding of von Wille-brand factor to platelet GPIba induced by conditions of high shear rate. Circulation 2002; 105: 2531-2536.
• 51 Hennan JK, Swillo RE, Morgan GA. et al. Pharmacologic inhibition of platelet VWF-GPIb alpha interaction prevents coronary artery thrombosis. Thromb Haemost 2006; 95: 469-475.
• 52 Goto S, Sakai H, Gito M. et al. Enhnaced shear-induced platelet aggregation in acute myocardial infarction. Circulation 1999; 99: 608-613.
• 53 Patrono C, Baigent C, Hirsh J. et al. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8^thedition). Chest 2008; 133: 199s-233s.
• 54 Herbert J, Frehel D, Vallee E. et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11: 180-198.
• 55 Gurbel P, Bliden K, Butler K. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease. The ONSET/OFFSET Study. Circulation 2009; 120: 2577-2585.
• 56 Price MJ, Coleman JL, Steinhubl SR. et al. Onset and offset of platelet inhibition after high dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol 2006; 98: 681-684.
• 57 Würtz M, Grove E, Wulff L. et al. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Inter 2010; 3: 828-835.
• 58 Grove E, Hvas AM, Kristensen S. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009; 101: 151-156.
• 59 Guthikonda S, Mangalpally K, Vaduganathan M. et al. Increased platelet sensitivity among individuals with aspirin resistance – platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. Thromb Haemost 2008; 100: 83-89.
• 60 Guthikonda S, Lev EI, Patel R. et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007; 5: 490-496.
• 61 Cesari F, Marcucci R, Caporale R. et al. Relationship between high platelet turnover and platelet function in high risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008; 99: 930-935.
• 62 Schonbeck U, Sukhova GK, Shimizu K. et al. Inhibition of CD40 signalling limits evolution of established atherosclerosis in mice. Proct Natl Acad Sci USA 2000; 97: 7458-7463.
• 63 Zhou Z, Penn MS, Forudi F. et al. Administration of recombinant P-selectin glycoprotein ligand Fc fusio protein suppresses inflammation and neointimal formation in Zucker diabetic rat model. Arterioscl Thromb Vasc Biol 2002; 22: 1598-1603.
• 64 Lutgens E, Cleutjens KB, Heeneman S. et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA 2000; 97: 7464-7469.
• 65 Heeschen C, Dimmeler S, Hamm C. et al. Soluble CD40 ligand in acute coronary syndromes. New Engl J Med 2003; 348: 1104-1111.
• 66 Aukrust P, Muller F, Ueland T. et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100: 614-620.
• 67 Yip HK, Chang LT, Sun CK. et al. Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting. Am J Cardiol 2006; 97: 192-194.
• 68 Xiao Z, Theroux P. Clopidogrel inhibits platelet-leucocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004; 43: 1982-1988.
• 69 Ridker PM. Cardiology patient page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation 2003; 108: e81-e85.
• 70 Vivekananthan D, Bhatt D, Chew D. et al. Effect of clopidogrel pre-treatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 2004; 94: 358-360.
• 71 Yu-guo C, Feng X, Yun Z. et al. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST segment elevation acute coronary syndrome. Chin Med J 2006; 119: 32-36.
• 72 Collet JP, Montalescot G, Steg PG. et al. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Arch Cardiovasc Dis. 2009; 102: 485-496.
• 73 Rogowski W, Burch J, Palmer S. et al. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis. Health Technol Assess 2009; 13: iii-iv ix-xi, 1–77.
• 74 Lordkipanidzé M, Diodati JG, Pharand C. Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence. Pharmacol Ther 2009; 123: 178-186.
• 75 http://www.clinicaltrials.gov/ct2/show/NCT00619073?term=PACT+trial&rank=12
• 76 Angiolillo D, Fernandez-ortiz A, Bernardo E. et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006; 55: 780-784.
• 77 Biondi-Zoccai GG, Abbate A, Liuzzo G. et al. Atherothrombosis, inflammation and diabetes. J Am Coll Cardiol 2003; 41: 1071-1077.
• 78 Wykrzykowska J, Warnholtz A, de Jaeger P. et al. Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-Selectin and CRP levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study. J Thromb Thrombolysis 2009; 28: 410-417.
• 79 Sibbing D, Stegherr J, Braun S. et al. A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. J Am Coll Cardiol 2010; 55: 558-565.
• 80 http://www.clinicaltrials.gov/ct2/show/NCT00684359?term=clopidogrel+rebound&rank=1
• 81 Armstrong PC, Dhanji AR, Truss NJ. et al. Utility of 96-well plate aggregometry and measurement of thrombin adhesion to determine aspirin and clopidogrel effectiveness. Thromb Haemost 2009; 102: 772-778.
• 82 Frelinger 3^rd AL, Furman MI, Linden MD. et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1– and cyclooxygenase-2-independent pathway. A 700 patient study of aspirin resistance. Circulation 2006; 113: 2888-2896.
• 83 Hobson AR, Agarwala AR, Swallow RA. et al. Thromboelastography: current clinical applications and its potential role in interventional cardiology. Platelets 2006; 17: 509-518.
• 84 Hobson A, Petley G, Dawkins K. et al. A novel 15 minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thromboelastography. Platelets 2007; 18: 497-505.
• 85 Sibbing D, Braun S, Morath T. et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
• 86 Gurbel P, Becker R, Mann K. et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822-1834.
• 87 Angiolillo D, Suryadevara S, Capranzano P. et al. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists. Cath Cardiovasc Int 2009; 73: 1-14.
• 88 Williams CD, Cherala G, Serebruany V. Application of platelet function testing to the bedside. Thromb Haemost 2010; 103: 29-33.
• 89 http://clinicaltrials.gov/ct2/show/NCT00640679?term=ISAR-CAUTION&rank=1
• 90 http://clinicaltrials.gov/ct2/show/NCT00827411?term=antiplatelet+therapy&rank=15
• 91 Husted S, Storey RF, Harrington RA. et al. Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin Cardiol 2010; 33: 206-212.
• 92 National Institute for Health and Clinical Excellence.. Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary interventions. Available at: http://guidance.nice.org.uk/TA182
• 93 Artang R, Dieter R. Analysis of 36 reported cases of late thrombosis in drug-eluting stents placed in coronary arteries. Am J Cardiol 2007; 99: 1039-1043.
• 94 Pfisterer M, Brunner-La Rocca HP, Buser P. et al for the BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-2591.
• 95 Jeremias A, Sylvia B, Bridges J. et al. Stent thrombosis after successful sirolimuseluting stent implantation. Circulation 2004; 109: 1930-1932.